Applying population mechanistic modelling to find determinants of chimeric antigen receptor T-cells dynamics in month-one lymphoma patients
This study shows how models can be used to link endogenous T-cells, CAR T-cells, and their phenotypes, and may be useful for determining whether a given patient may be responding poorly to treatment, by observing the dynamics of their endogenous T-cells. The framework we developed can be utilized for other CAR T constructs and indications, to test product alterations or biological hypotheses at the population level.
Authors
- Alexander V. Ratushny (ORCID: https://orcid.org/0000-0002-1701-4084)
- Mark Coles (ORCID: https://orcid.org/0000-0001-8079-9358)
- Eamonn A. Gaffney (ORCID: https://orcid.org/0000-0002-6888-4362)
- Robert Rosler
- Leanne Peiser
- Mark McConnell (ORCID: https://orcid.org/0000-0003-0978-2291)
- Liam Brown (ORCID: https://orcid.org/0000-0001-9870-8418)
- Brian J. Schmidt (ORCID: https://orcid.org/0000-0001-6015-9636)
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of Oxford (GB)
- Bristol-Myers Squibb (United States) (US)
- Institute of Rheumatology (CZ)
- Kennedy Center (DK)
- Mathematical Institute of the Slovak Academy of Sciences (SK)
Publication Details
- Journal
- Immunotherapy Advances
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1093/immadv/ltaf001
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00